Candice Horbacz
Within the intricate framework of the United States tax code, the treatment of research and development (R&D) expenditures serves as a critical determinant, influencing where, how, and indeed, whether American companies choose to innovate and invest. This policy landscape directly impacts the nation’s technological leadership, economic growth, and its standing in the global marketplace.
Currently, a notable divergence exists in the tax treatment of R&D. Under Section 174A of the US tax code, domestic R&D expenditures offer taxpayers a degree of flexibility: they can opt for immediate deduction, known as full expensing, or choose to amortize these costs over a period of at least 60 months (five years). While immediate expensing is generally more advantageous due to the time value of money, amortization might be selected by firms with specific financial situations, such as those with net operating losses, to spread deductions into future years. This flexibility provides a crucial incentive for domestic innovation, effectively reducing the upfront cost of research.
In stark contrast, foreign R&D expenditures are afforded no such discretion. Governed by Section 174, these costs must be capitalized and then amortized over a significantly longer period of 15 years, with no provision for immediate expensing. This creates a distinct disadvantage for US-based multinational corporations undertaking research activities outside the nation’s borders. The differing regimes have profound implications, raising questions about their efficacy in achieving stated policy goals and their potential unintended consequences for the US economy and its global competitiveness.
A Shifting Landscape: The Recent History of R&D Tax Treatment
The current bifurcated system is a relatively recent development, marking a significant shift from a long-standing policy of uniform R&D expensing. For decades, prior to the early 2020s, the US tax code generally allowed for the immediate deduction of all R&D expenses, irrespective of their geographic origin. This policy, enshrined in tax law since 1954, was widely considered a cornerstone of American innovation, fostering an environment where companies could rapidly reinvest in new discoveries without undue tax burdens.
However, the landscape began to change with the passage of the Tax Cuts and Jobs Act (TCJA) in 2017. While the TCJA introduced many sweeping changes to the corporate tax system, it also included a provision that, beginning in tax years after December 31, 2021, mandated the amortization of all R&D expenses. Specifically, domestic R&D would be amortized over five years, and foreign R&D over 15 years. This move was met with considerable criticism from industry groups and economists, including the Tax Foundation, who argued that it would stifle innovation by increasing the cost of R&D investment.
The original article refers to a legislative reversal for domestic R&D under what it calls the "One Big Beautiful Bill Act (OBBBA)," restoring the option for immediate expensing or 60-month amortization for domestic R&D, while maintaining the 15-year amortization for foreign R&D. This legislative action, if enacted as described, would have created the precise divergence observed today. Motivations behind such a targeted reversal for domestic R&D likely included a desire to reduce the overall budgetary cost of tax incentives while simultaneously aiming to encourage the onshoring of R&D activities, thereby bolstering domestic job creation and intellectual property development. However, this policy choice has generated substantial debate regarding its broader economic impact.
The Economic Underpinnings: Expensing vs. Amortization
At the heart of this policy debate lies a fundamental economic principle: the time value of money. The difference between immediate expensing and delayed amortization, while seemingly a matter of timing, profoundly impacts a firm’s investment decisions. Companies, when evaluating potential R&D projects, meticulously weigh present and future revenues, expenses, and, critically, tax payments.
This dynamic was eloquently explored by economists Robert Hall and Dale Jorgenson in their foundational 1967 research paper, which established a framework for understanding the user cost of capital. In their model, the user cost of capital, often denoted as c, represents the minimum hurdle rate a project must clear to justify investment. Any policy that increases c inherently discourages investment at the margin.
Under a regime of full expensing, where businesses can immediately deduct the entire cost of certain investments, the tax code has no impact on marginal investment. This means projects that are on the cusp of being worthwhile economically remain viable from a tax perspective. The Hall-Jorgenson framework demonstrates that when full expensing is in place, the present value of tax deductions effectively recovers the full cost of the investment immediately. This scenario causes the tax term in the cost-of-capital formula to cancel out entirely, making the effective marginal tax rate on a break-even investment zero. The government, in essence, returns a portion of the investment cost upfront, offsetting future tax collections on the income generated by a marginal project. This significantly lowers the hurdle rate for innovation, encouraging greater investment.
Conversely, amortization, particularly when stretched over 15 years as for foreign R&D, pushes the present value of tax deductions (z) significantly below 1. This delay in recovering costs through deductions means that the tax burden is positive, increasing the user cost of capital and raising the hurdle rate for investment. Projects that would be economically viable under full expensing may be abandoned purely for tax reasons under an amortization regime. This effectively acts as a disincentive, penalizing R&D activities and potentially suppressing innovation. For US-resident companies, domestic R&D can bypass this disincentive, while foreign R&D cannot, creating an uneven playing field.
It’s crucial to note that while full expensing neutralizes the tax burden on marginal investments, it does not imply a tax system that raises no revenue. Inframarginal investments—those whose benefits significantly outweigh their costs—would still incur a positive tax burden. Moreover, pre-existing investments continue to generate taxable income and tax revenue regardless of the depreciation schedule applied to new capital.
The Pitfalls of a Bifurcated System: Unintended Consequences
While the policy to differentiate R&D tax treatment might be motivated by a desire to onshore innovation and reduce budgetary costs, two significant drawbacks warrant serious consideration.
Firstly, reducing R&D investment abroad by making it less tax-efficient for US companies may, counterintuitively, diminish overall US production and investment rather than increase it. This perspective challenges the assumption that domestic and foreign R&D are always in direct competition. Many economists and industry experts argue that foreign R&D often complements, rather than substitutes for, domestic innovation.
Secondly, a less competitive global tax regime for US-resident companies could, at the margin, discourage US tax residence itself. If US multinationals face higher effective tax rates on their global R&D compared to competitors based in other nations, it could make the US a less attractive domicile for innovation-driven businesses, potentially leading to corporate inversions or the establishment of new global entities outside the US. This would not only reduce the US tax base but also erode the nation’s leadership in critical technological sectors.
International R&D: A Complement, Not a Substitute
The notion that domestic and international R&D are mutually exclusive and compete for the same investment dollars is often a mischaracterization. A substantial body of economic research and business observation indicates a strong complementarity between the two. Rather than simply displacing domestic activities, foreign R&D frequently enhances and scales them, creating a more robust and globally competitive innovation ecosystem for US companies.
One primary function of foreign R&D is market adaptation. For a US-developed product or service to succeed globally, it often requires significant customization. This can involve adapting software for foreign languages and payment systems, modifying hardware for different climates or infrastructure standards, or ensuring compliance with diverse foreign regulatory systems (ee.g., in automotive safety, telecommunications, or pharmaceutical clinical trials). Without this localized R&D, US companies would struggle to export their innovations, limiting their market reach and overall revenue potential, which in turn could curtail the resources available for domestic R&D.
Another common pattern involves the acquisition of foreign research teams or intellectual property. A valuable idea, a breakthrough technology, or a critical software patent developed outside the US can prove immensely useful to a large US company, which can then leverage its extensive infrastructure to scale and commercialize the innovation globally. To achieve this, the US company might make further substantial investments in its domestic operations, integrating the acquired foreign research into its existing R&D pipeline.
Leading economic research institutions and business organizations have consistently highlighted this complementarity. Economists Gary Hufbauer, Theodore Moran, and Lindsay Oldenski, in their work on outbound foreign direct investment, found that "global R&D expenditures and operations of US MNCs may create complementary capabilities and interdependent competencies, rather than simply displacing one capability or competency from location A to location B." Moran and Oldenski further argued that "measures to hinder or slow the globalization of R&D by US [multinational corporations] will stifle R&D by those multinationals in the United States." The Information Technology and Innovation Foundation (ITIF) has also concluded that offshore research tends to complement domestic innovation, often by accelerating localized product adaptation and expanding a firm’s broader knowledge network.
Collectively, this evidence suggests that penalizing foreign R&D is more likely to reduce a US company’s total cross-border knowledge production and innovation capacity than to generate net gains at home. It risks isolating US firms from global talent pools and cutting-edge research happening elsewhere.
Impact on Mergers and Acquisitions: A Competitive Disadvantage
The dynamic of acquiring foreign research teams merits particular attention, as the disparate tax treatment significantly impacts cross-border mergers and acquisitions (M&A). Harsher US tax rules on foreign R&D expenditures make US companies less competitive bidders when vying for R&D-heavy foreign acquisition targets.
Consider a scenario where a highly innovative, R&D-intensive foreign company is up for acquisition. If a US acquirer must amortize the target’s future R&D spending over 15 years, while a foreign competitor (from a country with more favorable R&D tax incentives, such as immediate expensing) can deduct those costs immediately, the US firm’s after-tax valuation of the target will be structurally lower. This inherent disadvantage can lead the US firm to lose the bidding war, missing out on critical technologies, talent, and market access.
The Semiconductor Industry Association (SIA) has specifically voiced concerns, arguing that US chip firms face a distinct disadvantage in global competition for innovative assets because foreign rivals often receive more favorable tax treatment for research spending. This insight, however, extends far beyond the semiconductor industry, impacting other M&A-heavy and R&D-intensive sectors like pharmaceuticals, biotechnology, software, and advanced manufacturing.
The loss of these cross-border M&A transactions carries multiple adverse consequences. Beyond the immediate harm to the US economy via the aforementioned complementarity, it reduces the global reach and revenue-generation capacity of US firms. Crucially, it also diminishes the purview of the US tax regime itself. Fewer successful foreign acquisitions by US companies mean fewer businesses operating under the US corporate umbrella, potentially leading to a smaller overall US tax base in the long run.
Broader Economic and Geopolitical Implications
The current R&D tax policy does not exist in a vacuum; it operates within a highly competitive global landscape where nations actively vie for technological leadership and economic dynamism. Many developed countries, including major trading partners and economic rivals, offer generous R&D tax incentives, often including immediate expensing or substantial tax credits, to encourage innovation within their borders and attract foreign investment. When the US imposes a comparatively less favorable regime for foreign R&D by its own companies, it creates a self-imposed handicap.
This policy can have significant ripple effects on the US innovation ecosystem. By making global R&D more costly for US multinationals, it may inadvertently limit their overall capacity for innovation, regardless of location. This could slow the pace of technological advancement, hinder the development of new products and services, and ultimately impact job creation within the US, particularly in high-skill sectors. Furthermore, it could undermine the US’s strategic objectives in maintaining leadership in critical technologies like AI, quantum computing, and advanced materials, where global collaboration and diverse research inputs are often essential.
Policy Recommendations and the Path Forward
To foster a more robust and globally competitive innovation environment, the United States should move decisively toward a neutral tax treatment of R&D expenditures, irrespective of where they occur. Policymakers must recognize the economic realities of multinational corporations and avoid creating disadvantages that disproportionately burden foreign R&D performed by US multinational enterprises (MNEs).
Restoring full expensing for all R&D, domestic and foreign, would eliminate the current disincentives and level the playing field for US companies competing on the global stage. This approach would encourage US firms to expand their overall innovation activity, improve their ability to compete for foreign acquisitions of critical technology and talent, and ultimately strengthen their global market position. Such a change would align US tax policy with the understanding that global R&D is often synergistic with domestic innovation, contributing to a stronger, more resilient, and more innovative American economy. Addressing this policy divergence is not merely a technical tax adjustment but a strategic imperative for securing the United States’ long-term economic prosperity and technological leadership.
